Neogap presents innovative tumour-targeting T-cell therapy at Neoantigen Summit Europe

Neogap Therapeutics, a biotech company specialising in personalised immunotherapy, has announced that Ola Nilsson, Head of Neoantigen Production and Development, will present the company’s innovative cell therapy pTTL at the 6th Annual Neoantigen Summit Europe in Amsterdam on the 24th – 26th of April.

The summit is dedicated to advancing personalised therapeutic development through the discovery of exclusive tumour antigens.

During the presentation, Ola Nilsson will showcase Neogap’s advanced software PIOR^® for neoantigen prediction and selection and the innovative EpiTCer^® technology for efficient antigen delivery, natural processing, and tumour-specific T-cell activation. These technologies are used in the company’s cell therapy pTTL (personalised Tumour Trained Lymphocytes), which targets neoantigens to combat cancer and is made from a patient’s T cells taken from nearby lymph nodes.

“We are thrilled to share our breakthrough technology with the world’s leading experts in neoantigen discovery and development. This is a great opportunity to showcase Neogap’s commitment to advancing personalised immunotherapy,” says Ola Nilsson.

With over 150 experts in attendance, the Neoantigen Summit Europe is the ideal forum for discussing the validation of neoantigen targets and reviewing methodologies and technologies to support translating neoantigen-based studies effectively to the clinic.